These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The Trump administration has promised that addressing childhood obesity will be a key part of its “Make America Healthy Again ...

The luster is starting to wear off GLP-1 weight-loss drugs including Wegovy and Ozempic as more clinicians warn patients ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the FDA.

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

A battle over how to treat childhood obesity is brewing between those in favour and others who warn of the effects on growing bodies ...